Merck, Eisai post mixed Phase 3 data for Keytruda/ Lenvima in GIT cancer
Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Japanese ...
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.
Labs, housing could soon rise where Simmons College dorms now stand
The local arm of Swedish building giant Skanska is moving forward with its plan to redevelop the residential campus of ...
Merck and Eisai report mixed results in Phase 3 cancer trial
Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...
Father knows best? Liverpool winning but manager’s dad wants more action
Arne Slot's dad wasn't impressed with Liverpool's midweek win over Lille in the Champions League. The Liverpool manager ...
Tenants want province to buy Gorge apartments set for redevelopment
Victoria city council approved the first steps of a plan that would see the three nearly identical 1970-era apartments on ...